Last €45.96 EUR
Change Today +0.56 / 1.23%
Volume 101.4K
IPN On Other Exchanges
Symbol
Exchange
EN Paris
OTC US
OTC US
As of 11:35 AM 03/2/15 All times are local (Market data is delayed by at least 15 minutes).

ipsen (IPN) Snapshot

Open
€45.60
Previous Close
€45.40
Day High
€46.48
Day Low
€45.54
52 Week High
03/2/15 - €46.48
52 Week Low
04/11/14 - €28.24
Market Cap
3.8B
Average Volume 10 Days
63.4K
EPS TTM
€1.88
Shares Outstanding
82.9M
EX-Date
05/29/15
P/E TM
24.4x
Dividend
€0.85
Dividend Yield
1.74%
Current Stock Chart for IPSEN (IPN)

Related News

No related news articles were found.

ipsen (IPN) Related Businessweek News

View More BusinessWeek News

ipsen (IPN) Details

Ipsen S.A. operates as a pharmaceutical company worldwide. It offers drugs in the areas of uro-oncology, endocrinology, neurology, gastroenterology, cardiovascular, and cognitive disorders. The company’s products include Decapeptyl, a peptide formulation for injection in the treatment of advanced prostate cancer; Hexvix that is used to enhance detection of bladder cancer; and Somatuline and Somatuline Autogel, which are used in the treatment of acromegaly and neuroendocrine tumours. Ipsen S.A. also offers NutropinAq, a liquid formulation used in the treatment of growth failure in children and growth hormone deficiency in adults; Increlex, a formulation used for the long-term treatment of growth failure in children and adolescents with severe primary insulin-like growth factor 1 deficiency; and Dysport, a botulinum neurotoxin type A complex used to treat spasticity of upper limbs following a stroke, as well as the spasticity of other muscles. In addition, it provides Smecta, a natural clay-based drug used in the treatment of chronic and acute diarrhea; Forlax, a drug based on a linear polyethylene glycol polymer used in the treatment of constipation; and Tanakan that is used in the treatment of age-related cognitive disorders. Further, the company offers Nisis and Nisisco oral formulations containing valsartan used in the treatment of hypertension; and Adenuric for the treatment of gout. Additionally, it is developing products in the areas of neurology, endocrinology, and uro-oncology, including BN82451, Tasquinimod, Somatuline Autogel, Dysport, Dysport Next Generation, and Decapeptyl. The company was founded in 1929 and is headquartered in Boulogne-Billancourt, France. Ipsen S.A. is a subsidiary of Mayroy S.A.

4,602 Employees
Last Reported Date: 03/26/14
Founded in 1929

ipsen (IPN) Top Compensated Officers

Chairman, Chief Executive Officer and Member ...
Total Annual Compensation: €1.4M
Deputy Chief Executive Officer and Interim Ex...
Total Annual Compensation: €1.1M
Compensation as of Fiscal Year 2013.

ipsen (IPN) Key Developments

Ipsen S.A. Announces Unaudited Consolidated Sales Results for the Fourth Quarter and Full Year 2014

Ipsen S.A. announced unaudited consolidated sales results for the fourth quarter and full year 2014. For the quarter, the company announced group sales of EUR 307.1 million compared to EUR 293.0 million for the same period a year ago. For the full year, the company announced group sales of EUR 1,274.8 million compared to EUR 1,224.8 million for the same period a year ago.

Ipsen Announces Topline Results of Two Double-Blind Phase III Studies of Dysport® in Lower Limb Spasticity in Children and Adults

Ipsen announced topline results for two double-blind phase III studies of Dysport® (abobotulinumtoxinA) in Pediatric Lower Limb (PLL) spasticity in children with cerebral palsy and in Adult Lower Limb (ALL) spasticity in patients who had experienced a stroke or traumatic brain injury. In the PLL phase III study, conducted in children with hemiparetic or diplegic cerebral palsy, treatment with Dysport® showed a statistically significant response versus placebo in the improvement of muscle tone, as measured by the Modified Ashworth Scale (MAS; primary endpoint), and a statistically significant overall benefit versus placebo, as measured by the Physician Global Assessment (PGA; first secondary endpoint). In the ALL phase III study, conducted in hemiparetic patients who had experienced a stroke or traumatic brain injury, treatment with Dysport® at the dose of 1500U showed a statistically significant response versus placebo in the improvement of muscle tone, as measured by the Modified Ashworth Scale (MAS; primary endpoint). An overall benefit (measured by the Physician Global Assessment (PGA); first secondary endpoint) versus placebo was observed but did not reach statistical significance according to the pre-specified statistical analysis. Other spasticity and functional outcome results are currently being analyzed. The safety profile observed in the studies was consistent with the known safety profile of Dysport® in these indications. Comprehensive results from these double-blind studies will be disclosed in the next few months at major international congresses. Ipsen will share these results with key regulatory agencies this year. The Phase III study conducted in children with cerebral palsy included 235 patients and was multicentric, prospective, double blind, randomized, and placebo-controlled. It was conducted in the USA, France, Turkey, Poland, Mexico and Chile. The purpose of this study in children was to assess the efficacy and safety of Dysport® compared to placebo in improving lower limb spasticity in hemiparetic or diplegic cerebral palsy patients. The phase III study in adults suffering from lower limb spasticity included 388 patients and was international, multicentric, prospective, double blind, randomized and placebo-controlled. It was conducted in the USA, France, Italy, Belgium, Czech Republic, Poland, Slovakia, Russia and Hungary. The purpose of this study was to assess the efficacy and safety of Dysport® compared to placebo in improving lower limb spasticity in hemiparetic adult patients who had experienced a stroke or a traumatic brain injury. The primary endpoint for both studies was the improvement of muscle tone in the treated lower limb measured by the Modified Ashworth Scale (MAS). Patients were offered to continue in an open label long-term study wherein they will be receiving additional Dysport® treatment cycles within a total of 15 months.

Ipsen S.A. to Report Fiscal Year 2014 Sales/Trading Statement Results on Feb 03, 2015

Ipsen S.A. announced that they will report fiscal year 2014 sales/trading statement results on Feb 03, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IPN:FP €45.96 EUR +0.56

IPN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Almirall SA €13.80 EUR +0.28
Meda AB kr135.20 SEK +0.20
Orion Oyj €28.92 EUR -0.17
Procter & Gamble Hygiene & Health Care Ltd 7,000 INR -43.40
Recordati SpA €16.24 EUR +0.15
View Industry Companies
 

Industry Analysis

IPN

Industry Average

Valuation IPN Industry Range
Price/Earnings 19.7x
Price/Sales 2.4x
Price/Book 3.1x
Price/Cash Flow 18.7x
TEV/Sales 2.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IPSEN, please visit www.ipsen.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.